Equities Analysts Offer Predictions for KALV FY2030 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for KalVista Pharmaceuticals in a research report issued on Friday, January 9th. HC Wainwright analyst A. Fein expects that the specialty pharmaceutical company will post earnings per share of $5.90 for the year. HC Wainwright currently has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million.

Other analysts also recently issued reports about the company. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Needham & Company LLC lifted their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $16.39 on Monday. The firm has a market capitalization of $828.51 million, a price-to-earnings ratio of -4.15 and a beta of -0.14. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The business’s 50 day simple moving average is $14.68 and its 200-day simple moving average is $13.65. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $19.00.

Insider Activity

In related news, CFO Brian Piekos sold 4,471 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the transaction, the chief financial officer owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 31,329 shares of company stock valued at $437,371 over the last 90 days. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in KALV. Emerald Mutual Fund Advisers Trust boosted its holdings in shares of KalVista Pharmaceuticals by 26.4% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 768,972 shares of the specialty pharmaceutical company’s stock valued at $8,693,000 after purchasing an additional 160,759 shares during the last quarter. Emerald Advisers LLC increased its holdings in shares of KalVista Pharmaceuticals by 15.6% during the 2nd quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock worth $11,735,000 after buying an additional 139,859 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of KalVista Pharmaceuticals by 364.0% in the 2nd quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company’s stock worth $1,130,000 after buying an additional 78,450 shares during the period. F m Investments LLC boosted its holdings in KalVista Pharmaceuticals by 263.8% in the second quarter. F m Investments LLC now owns 182,262 shares of the specialty pharmaceutical company’s stock valued at $2,060,000 after acquiring an additional 132,165 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 3.4% in the first quarter. Rhumbline Advisers now owns 52,918 shares of the specialty pharmaceutical company’s stock valued at $611,000 after acquiring an additional 1,762 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.